VRN 11
Alternative Names: VRN-11; VRN-110755Latest Information Update: 24 Aug 2026
At a glance
- Originator Voronoi
- Class Antineoplastics; Small molecules
- Mechanism of Action ErbB receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 02 Jun 2026 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Non-small cell lung cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 22 Apr 2026 Efficacy, adverse event and pharmacokinetic data from phase I trial in Non small cell lung cancer presented at 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 16 Apr 2026 Voronoi completes phase I trial for Non-small cell lung cancer (In volunteers) in Australia (PO) (NCT07141381)